ALL Eyes On PRPH, TNDM Soars On Analyst Upgrade, OMER Back In Focus

(RTTNews) - The following are some of today's top gainers in the pharma/biotech sector.

1. ProPhase Labs Inc. (PRPH)

Gained 26.76% to close Monday's (May 14) trading at $5.21.

News: No news

ProPhase is a marketer and distributor of a diversified range of over-the-counter ("OTC") dietary supplements.

Near-term Catalyst:

The Company is slated to report financial results for the first quarter ended March 31, 2018, this week.

2. Tandem Diabetes Care Inc. (TNDM)

Gained 25.22% to close Monday's trading at $11.14.

News: Piper Jaffray analyst JP McKim upgraded Tandem to "Overweight" from "Neutral", and boosted his price target on the stock to $13.00 from $8.00.

Recent event:

On April 26, 2018, the Company reported its financial results for the quarter ended March 31, 2018. Sales in the first quarter increased 44 percent to $27.3 million from $19.0 million in the comparable year-ago quarter.

For the year ending December 31, 2018, the Company expects sales to be in the range of $132 million to $140 million, which represents an annual sales growth of 23 percent to 30 percent compared to 2017.

Near-term Catalyst: The Company will make a presentation at the Bank of America Merrill Lynch 2018 Healthcare Conference on May 15, 2018 at 12:35 PM Eastern Time (9:35 AM Pacific Time).

3. Myomo Inc. (MYO)

Gained 23.25% to close Monday's trading at $3.87.

Myomo is a wearable medical robotics company.

News: The Centers for Medicare & Medicaid Services (CMS) has published a favorable preliminary decision regarding the Company's application for Healthcare Common Procedure Coding System (HCPCS) "L" codes.

If the decision is made permanent, the codes will become effective on January 1, 2019. The assignment of unique L-Codes, if followed by appropriate payment terms (which are still pending), would offer greater access to the Company's MyoPro, a myoelectric elbow/wrist/hand orthosis (powered brace), for Medicare beneficiaries.

4. BioDelivery Sciences International Inc. (BDSI)

Gained 20.59% to close Monday's trading at $2.05.

News: No news

Recent event:

On May 10, 2018, the Company reported financial results for the first quarter ended March 31, 2018 and provided an update on recent business highlights.

Net loss for the recent first quarter was $10.6 million or $0.18 per share on total net revenue of $11.3 million. This compared with a net income of $48.3 million or $0.87 per share and revenue of $9.5 million in the year-ago quarter.

At March 31, 2018, the Company had cash of approximately $12.1 million.

5. ENDRA Life Sciences Inc. (NDRA)

Gained 17.89% to close Monday's trading at $2.90.

ENDRA is developing a next generation Thermo-Acoustic Enhanced UltraSound (TAEUS) system that will help clinicians to visualize tissue function, composition, and monitor a variety of therapeutic interventions at the point of care.

The first TAEUS application will focus on the quantification of fat in the liver, for early detection and monitoring of Non-Alcoholic Fatty Liver Disease.

News: The Company is slated to report first-quarter financial results on May 15, 2018.

6. MabVax Therapeutics Holdings Inc. (MBVX)

Gained 17.86% to close Monday's trading at $1.65.

News: No news

Near-term Catalyst:

Full data report from phase I trial of MVT-5873 in combination with Gem/nab in first line treatment of näive pancreatic ductal adenocarcinoma (PDAC) patients is expected in mid-year 2018.

7. Asterias Biotherapeutics Inc. (AST)

Gained 17.24% to close Monday's trading at $1.70.

News: No news

Near-term Catalysts:

-- The first-in-human clinical trial of AST-VAC2 in non-small cell lung cancer is expected to begin this quarter (Q2, 2018). -- Six-month update for the entire SCiStar study, including Cohort 5, is expected to be provided late in the second quarter or early third quarter of 2018. SCiStar study is a phase I/II trial of AST-OPC1 in Spinal Cord Injury. -- 12-month update for Cohorts 3 and 4 of the SCiStar study is anticipated in the third quarter of 2018. -- 24-month update for Cohort 2 of the SCiStar study is expected in the third or fourth quarter of 2018. -- 12-month update for the entire SCiStar study, including Cohort 5, is expected late in the fourth quarter of 2018 or early in the first quarter of 2019.

8. Omeros Corp. (OMER)

Gained 13.98% to close Monday's trading at $22.67.

News: No news

Recent event:

On May 10, 2018, the Company reported financial results for the first quarter ended March 31, 2018, and also provided an update on its pipeline.

For the recent first quarter, the net loss widened to $30.1 million or $0.62 per share from $15.1 million or $0.34 per share in the year-ago quarter.

Revenues were $1.6 million for the first quarter of 2018, all relating to sales of OMIDRIA. This compares to OMIDRIA revenues of $12.3 million for the same period in 2017. The plunge in OMIDRIA revenue is attributable to reduced Ambulatory Surgical Center (ASC) and hospital purchasing following the scheduled loss of pass-through reimbursement status as of January 1, 2018.

However, as part of the Consolidated Appropriations Act, the pass-through status for OMIDRIA was reinstated for a two-year period, effective October 1, 2018 through September 30, 2020.

The Company also revealed that it has made tremendous progress in the development of its phase III drug candidate OMS721, its lead human monoclonal antibody in its mannan-binding lectin-associated serine protease-2 (MASP-2) programs for the treatment of HSCT-TMA, IgA nephropathy, and atypical hemolytic uremic syndrome (aHUS).